Single-Piece Syndrome

The newest form of IOL-induced glaucoma.

BY GARRY P. CONDON, MD

The AcrySof line (Alcon Laboratories, Inc., Fort Worth, TX) of single-piece hydrophobic acrylic IOLs has become tremendously popular since its introduction in 2000, and these lenses can now be inserted through incisions as small as 2.2 mm.1 Thanks to their soft foldable optics and large, square-edged, floppy haptics, these lenses are easily injected into the capsular bag in a gentle, controlled fashion. Leaving any part of the lens outside the bag and in direct contact with the posterior surface of the iris, however, often results in iris chafing with pigment dispersion that can cause IOP elevation, a microscopic hemorrhage, and chronic inflammation. A number of recent reports have documented the potential for single-piece acrylic IOLs, and in particular their haptics, to produce uveitis-glaucoma-hyphema (UGH) syndrome when they are placed either partly or completely in the sulcus.2-4

Despite a growing awareness of this problem, many glaucoma surgeons continue to see patients on long-term suboptimal treatment for UGH syndrome associated with malpositioning of this particular IOL. A number of factors may explain the lack of more immediate recognition of the problem and earlier effective treatment. First, the UGH syndrome in these cases typically has a somewhat delayed onset—greater than 12 months in one study.5 For that reason, the underlying problem may often be missed or forgotten. Second, in the past, if cataract surgery were complicated by posterior capsular rupture, implanting this IOL entirely in the sulcus was deemed acceptable.6 Moreover, in cases of pseudoexfoliation and zonular compromise, the asymmetrical implantation of the IOL, with one haptic in the capsular bag and the other in the sulcus, was not recognized as a problem.

The delayed onset of UGH and its initially mild symptoms in these patients often leads to ineffective medical treatment for several years, while a progressive escalation in pigment dispersion and iris trauma produces worsening glaucoma, inflammation, and microhyphema.

In 2010, the FDA approved the Softec HD lens (Lenstec, Inc., St. Petersburg, FL). This single-piece hydrophobic acrylic IOL has a profile similar to that of the AcrySof IOL. The potential of the former to produce single-piece syndrome has yet to be evaluated.

THE FALLACY OF THE APPARENTLY WELL-POSITIONED IOL

When these patients present years after their original cataract surgery to the uveitis or glaucoma consultant, he or she often does not immediately recognize the true malpositioning of the IOL. If the lens is entirely in the sulcus, the pliability of its haptics allows the optic of the lens to appear remarkably well centered. A careful slit-lamp examination with retroillumination will usually clearly reveal a pattern of loss in the iris pigment layer that directly outlines the configuration of one or both haptics.

Moreover, in cases of pseudoexfoliation and zonular compromise, the asymmetrical implantation of the IOL, with one haptic in the capsular bag and the other in the sulcus, was not recognized as a problem.

The delayed onset of UGH and its initially mild symptoms in these patients often leads to ineffective medical treatment for several years, while a progressive escalation in pigment dispersion and iris trauma produces worsening glaucoma, inflammation, and microhyphema.

In 2010, the FDA approved the Softec HD lens (Lenstec, Inc., St. Petersburg, FL). This single-piece hydrophobic acrylic IOL has a profile similar to that of the AcrySof IOL. The potential of the former to produce single-piece syndrome has yet to be evaluated.
could result in a vitreous hemorrhage. I have seen a number of such patients who have undergone repeat pars plana vitrectomy by a vitreoretinal surgeon who has not considered exchanging the IOL. Indeed, he or she often may feel that the lens is perfectly positioned because of its excellent centration. The unique features of the pliable-yet-sharp haptics and the planar configuration of this IOL disguise its malposition and yet propagate unrelenting pigment epithelial and irido-vascular trauma.

**IT ONLY GETS WORSE**

It is certainly reasonable to prescribe ocular hypotensive and anti-inflammatory medications as initial therapy in patients who develop an UGH syndrome from a malpositioned single-piece IOL. Even if their initial response is excellent, however, they require close observation. Unfortunately, medical therapy in the vast majority of these cases is inadequate but often continues for several years, allowing the process to escalate and the trabecular meshwork and iris microvasculature to deteriorate (Figure 2). In my experience, patients are too often advised against an IOL exchange simply because the position of the lens looks “too good.” Delaying surgery to replace the lens can result in progressive glaucomatous damage to the optic disc and an inability to regain control of the IOP after removal of the offending IOL. The reality is that this entire dilemma can be cured with surgery, and I have found that a majority of these patients readily agree to surgery after spending years trying unsuccessfully to control their problem.
DEFINITIVE SURGICAL THERAPY

Early IOL exchange surgery is the best option if the patient is symptomatic from smoldering, persistent, low-grade uveitis or if his or her IOP is uncontrolled. When only one haptic extends outside the capsular bag, an alternative approach is to amputate the offending haptic at the edge of the capsular bag to eliminate any further contact with the iris. Both of these surgical options are well within the capability of an anterior segment surgeon with readily available microforceps and microscissors.

Preoperatively, I try to determine whether the majority of the IOL is outside the capsular bag or whether only a single offending haptic is anterior to the capsular bag. I also want to know whether the posterior capsule is open so that I am prepared to perform any required partial vitrectomy if the lens is to be exchanged. In an eye with pseudoexfoliation, there is always the possibility of an absent zonule. Any areas where the zonule is open need to be determined at the time of surgery, prior to manipulations of the IOL. Iris retractors can be extremely beneficial for visualizing peripheral structures of the capsule and zonule during surgery (Figure 3).

In my experience, most cases involve an asymmetrically positioned IOL, with one half outside the capsular bag and the other half within the fornix of the capsular bag. In these cases, the haptic correctly located in the capsular bag is often solidly fibroed into position. It is best, then, to amputate this haptic at the edge of the capsularhesis with microscissors rather than to attempt to remove it and risk tearing the capsular bag or zonule. Any portion of the lens that remains well within the capsular bag can be left behind for the purposes of the IOL exchange (Figure 4). I instill a generous amount of viscoelastic to protect the corneal endothelium and tamponade any areas of potential vitreous prolapse. This measure combined with the use of iris retractors, microforceps, and microscissors will usually allow for uneventful, controlled surgery. I have found that topical tetracaine and intracameral 1.5% unpreserved lidocaine are usually adequate for anesthesia.

I approach the eye temporally with a clear corneal 2.4-mm incision and additional paracentesis tracts to allow for hooks and microforceps, as needed. The initial instillation of the viscoelastic usually reveals which portion of the IOL is outside the capsular bag. There are a number of options for removing the single-piece acrylic IOL once it has been freed from any capsular attachments. I prefer to use the IOL grasper and scissors from MicroSurgical Technology (Redmond, WA) to remove a pie-shaped portion of the optic first. The remaining piece of IOL is then in a configuration that can be easily pulled through the 2.4-mm incision (Figure 5). In cases where all but one haptic of the IOL is contained within the capsular bag, I simply amputate the offending haptic as close to the optic as possible by means of the horizontal microscissors or the vertical Rappazzo scissors (Figure 3).

I favor a large-diameter three-piece silicone IOL (model AQ2010; STAAR Surgical Company, Monrovia, CA) as a replacement lens. This IOL has an overall diameter of 13.5 mm, an optical diameter of 6.3 mm, and a round-edged anterior optic. The lens is vaulted and must be correctly oriented. It can be manually folded or placed in an injector. For safe, controlled insertion of the lens, it is necessary to enlarge the corneal incision to at least 3 mm. I typically inject the entire lens into the
anterior chamber and confirm that it is correctly orient-
ed before placing each haptic in the sulcus with micro-
forceps (Figure 6). Although it may be possible to
capture the optic of the lens with any residual capsular
opening, I do not find that step necessary, given the
overall size and optical diameter of this IOL. An alterna-
tive would be a three-piece acrylic IOL, for which I
would prefer posterior capture of the optic because of
its smaller diameter and square edges.

In high myopes with large anterior segment diameters, I
consider using iris sutures to fixate the IOL and reduce
any rotational instability. It is important to reduce the
power of the IOL when placing it in the sulcus. I generally
decrease the lens’ power by 1.00 D, but that adjustment is
based on the overall power of the IOL.

THE BOTTOM LINE

A patient with persistent, recurrent, low-grade signs and
symptoms of chronic inflammation associated with pig-
ment dispersion and elevated IOP needs to be carefully
evaluated for the possibility of a malpositioned single-piece
acrylic IOL. The vast majority of these patients will require
IOL surgery to effectively resolve the problem. If this proce-
dure is performed early enough in their clinical course, very
few will require surgical intervention for any secondary
glaucoma.

A video of Dr. Condon’s surgical management of a malpo-
sitioned single-piece IOL is available at http://eyetube.net/?v=gufan.

Garry P. Condon, MD, is an associate professor
of ophthalmology at Drexel University College of
Medicine, a clinical associate professor at the
University of Pittsburgh, and the chairman of the
Department of Ophthalmology at Allegheny
General Hospital in Pittsburgh. He receives speaker’s honoraria
and consulting fees from Alcon Laboratories, Inc. Dr. Condon
may be reached at (412) 359-6298; garrycondon@gmail.com.

2005;31:1421-1427.
4. Winne R, Austin M. Pigment dispersion with elevated intraocular pressure after AcrySof
5. Uy HS, Chan PS. Pigment release and secondary glaucoma after implantation of single-
piece acrylic intracocular lenses in the ciliary sulcus. Am J Ophthalmol. 2006;142(2):330-
332.
tion in the sulcus in eyes with posterior capsule tear during phacoemulsification. J Cataract